All News

Research from the Heart Failure Society of America Annual Scientific Meeting evaluated remote physiological monitoring for treating systolic heart failure (HF), as well as the impact of a heart transplant allocation system on urban and rural communities.

A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).

Chronic obstructive pulmonary disease (COPD) presents a significant challenge for both patients and health care providers and discussions of effective management strategies took center stage at CHEST 2024 in Boston.

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, discusses key agenda highlights that will be presented at the 2024 AMCP Nexus conference.

CNTN1 and NRXN3 clearly differentiated severe and milder forms of spinal muscular atrophy (SMA).

Three patients with RPE65-related retinopathy showed improved function in both eyes following gene augmentation therapy treatment with voretigene neparvovec.

As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians

A poster presented at the CHEST 2024 annual meeting shows that inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD).

Study findings reveals a 1-way relationship between cardiovascular disease and psoriasis, with no impact on other immune-mediated inflammatory diseases.

It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for support.

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.

Hope is on the horizon for patients living with chronic obstructive pulmonary disease (COPD). CHEST 2024 in Boston featured a session highlighting emerging bronchoscopic therapies.

CMS actuaries foresee a gradual rise in per capita health spending, slowing initially but eventually outpacing economic growth.

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive pulmonary disease (COPD).

The suggestive evidence should encourage research into the associations to evaluate the association with stronger evidence.

A systematic review analyzing sleep quality and the impact of zinc supplements reveals glaring gaps in knowledge in this area despite suggested benefits, demonstrating the need for future research.

New data presented at CHEST 2024 in Boston revealed a significant link between obstructive sleep apnea and mental health disorders in middle-aged and older adults.

At the CHEST 2024 annual meeting, international respiratory society leaders highlighted the need for global collaboration to address issues like air pollution and health equity in respiratory care.

Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).

Recent results from a new diabetes reversal program demonstrate the reliable, sustained benefits of nonpharmacological interventions in the management of diabetes and overall health of patients.

Between 2011 and 2020, the Veterans Health Administration spent $78 billion on health services for veterans also enrolled in Medicare Advantage.

The Heart Failure Society of America (HFSA) annual meeting 2024 was scheduled to showcase groundbreaking research on the impact of COVID-19 on patients with myocarditis and heart failure.

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.

A phase 3b study found that Black individuals who switched to bictegravir/emtricitabine/tenofovir alafenamide were able to maintain virologic suppression after 72 weeks.

Krunal Patel, MD, Temple University Hospital, highlights CHEST 2024 data revealing why timing matters with acute pulmonary embolism (PE) intervention.

The updated guidelines from the US Preventive Services Task Force (USPSTF) have led to an increase in screening for colorectal cancer (CRC) in individuals aged 45 to 49 years.

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.

Experts at the CHEST 2024 annual meeting agreed that artificial intelligence (AI) should not be relied upon entirely, but instead be used as a tool by radiologists to make a diagnosis of interstitial lung disease (ILD).

Less than a third of FDA-mandated trials for drugs approved between 2015 and 2021 had been completed by May 2024.